

MAP Pharmaceuticals, Inc.

Form 3

October 04, 2007

**FORM 3**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB  
Number: 3235-0104Expires: January 31,  
2005Estimated average  
burden hours per  
response... 0.5**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting  
Person \*Skyline Venture Partners  
Qualified Purchaser Fund III,  
L.P.

(Last) (First) (Middle)

125 UNIVERSITY  
AVENUE,, GARDEN LEVEL

(Street)

PALO ALTO, CA 94301

(City) (State) (Zip)

2. Date of Event Requiring  
Statement(Month/Day/Year)  
10/04/20073. Issuer Name and Ticker or Trading Symbol  
MAP Pharmaceuticals, Inc. [MAPP]4. Relationship of Reporting  
Person(s) to Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_X\_\_\_\_ 10% Owner  
\_\_\_\_ Officer \_\_\_\_ Other  
(give title below) (specify below)5. If Amendment, Date Original  
Filed(Month/Day/Year)6. Individual or Joint/Group  
Filing(Check Applicable Line)  
\_X\_ Form filed by One Reporting  
Person  
\_\_\_\_ Form filed by More than One  
Reporting Person**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security  
(Instr. 4)2. Amount of Securities  
Beneficially Owned  
(Instr. 4)3. Ownership  
Form:  
Direct (D)  
or Indirect  
(I)  
(Instr. 5)4. Nature of Indirect Beneficial  
Ownership  
(Instr. 5)Reminder: Report on a separate line for each class of securities beneficially  
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form displays a  
currently valid OMB control number.****Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative  
Security  
(Instr. 4)2. Date Exercisable and Expiration  
Date  
(Month/Day/Year)3. Title and Amount of  
Securities Underlying  
Derivative Security  
(Instr. 4)4. Conversion  
or Exercise  
Price of  
Derivative5. Ownership  
Form of  
Derivative  
Security:6. Nature of  
Indirect Beneficial  
Ownership  
(Instr. 5)

Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
10/10/2007 <sup>(2)</sup>	10/10/2007 <sup>(3)</sup>	Common Stock	779,871 <sup>(4)</sup>	\$ 0 <sup>(5)</sup>	I	See footnote <sup>(6)</sup>
10/10/2007 <sup>(2)</sup>	10/10/2007 <sup>(3)</sup>	Common Stock	320,690 <sup>(4)</sup>	\$ 0 <sup>(5)</sup>	I	See footnote <sup>(7)</sup>
10/10/2007 <sup>(2)</sup>	10/10/2007 <sup>(3)</sup>	Common Stock	538,236 <sup>(4)</sup>	\$ 0 <sup>(5)</sup>	I	See footnote <sup>(8)</sup>

$$\hat{A} \quad \hat{A} \times \hat{A} \quad \hat{A} \quad \hat{A}$$

## Edgar Filing: MAP Pharmaceuticals, Inc. - Form 3

respect to the shares of Series D Preferred Stock held by SVPIII, SVPQFIII, and John Freund and Yasunori Kaneko as Managing Directors of SVMIII may be deemed to share voting and investment power with respect to the shares of Series D Preferred Stock held by SVPIII and SVPQFIII. The reporting persons/entities disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.